326 related articles for article (PubMed ID: 31433680)
1. Economic burden of fatigue or morning stiffness among patients with rheumatoid arthritis: a retrospective analysis from real-world data.
Strand V; Shah R; Atzinger C; Zhou J; Clewell J; Ganguli A; Tundia N
Curr Med Res Opin; 2020 Jan; 36(1):161-168. PubMed ID: 31433680
[No Abstract] [Full Text] [Related]
2. Economic Burden of Patients with Inadequate Response to Targeted Immunomodulators for Rheumatoid Arthritis.
Strand V; Tundia N; Song Y; Macaulay D; Fuldeore M
J Manag Care Spec Pharm; 2018 Apr; 24(4):344-352. PubMed ID: 29578852
[TBL] [Abstract][Full Text] [Related]
3. Economic burden of irritable bowel syndrome with constipation: a retrospective analysis of health care costs in a commercially insured population.
Doshi JA; Cai Q; Buono JL; Spalding WM; Sarocco P; Tan H; Stephenson JJ; Carson RT
J Manag Care Spec Pharm; 2014 Apr; 20(4):382-90. PubMed ID: 24684643
[TBL] [Abstract][Full Text] [Related]
4. Burden of illness and costs associated with eosinophilic granulomatosis with polyangiitis: evidence from a managed care database in the United States.
Bell CF; Blauer-Peterson C; Mao J
J Manag Care Spec Pharm; 2021 Sep; 27(9):1249-1259. PubMed ID: 34165321
[No Abstract] [Full Text] [Related]
5. Health Care Resource Utilization and Cost Before Initial Schizophrenia Diagnosis.
Wallace A; Barron J; York W; Isenberg K; Franchino-Elder J; Sidovar M; Sand M
J Manag Care Spec Pharm; 2019 Oct; 25(10):1102-1110. PubMed ID: 31556820
[TBL] [Abstract][Full Text] [Related]
6. Economic Evaluation of Anticyclic Citrullinated Peptide Positivity in Rheumatoid Arthritis.
An J; Bider-Canfield Z; Kang J; Alemao E; Connolly SE; Lin AT; Cheetham TC
J Manag Care Spec Pharm; 2019 Apr; 25(4):469-477. PubMed ID: 30917075
[TBL] [Abstract][Full Text] [Related]
7. Economic Burden of Switching to a Non-Tumor Necrosis Factor Inhibitor Versus a Tumor Necrosis Factor Inhibitor Biologic Therapy among Patients with Rheumatoid Arthritis.
Zhou ZY; Griffith J; Du EX; Chin D; Betts KA; Ganguli A
Adv Ther; 2016 May; 33(5):807-23. PubMed ID: 27084724
[TBL] [Abstract][Full Text] [Related]
8. Economic burden of sarcoidosis in a commercially-insured population in the United States.
Rice JB; White A; Lopez A; Conway A; Wagh A; Nelson WW; Philbin M; Wan GJ
J Med Econ; 2017 Oct; 20(10):1048-1055. PubMed ID: 28678623
[TBL] [Abstract][Full Text] [Related]
9. Healthcare resource utilization and costs among patients with rheumatoid arthritis on biologic therapies in Taiwan: A 1-year mirror-image study using a national claims database.
Chen KC; Wu CH; Tang CH; Huang KC
PLoS One; 2018; 13(7):e0200758. PubMed ID: 30020997
[TBL] [Abstract][Full Text] [Related]
10. Health Care Effect of Disease-Modifying Antirheumatic Drug Use on Patients with Rheumatoid Arthritis.
Boytsov NN; Bhattacharya R; Saverno K; Dixon L; Abbott PL; Zhang X; Gaich CL; Nair R
J Manag Care Spec Pharm; 2019 Aug; 25(8):879-887. PubMed ID: 31347977
[TBL] [Abstract][Full Text] [Related]
11. The economic burden of switching targeted disease-modifying anti-rheumatic drugs among rheumatoid arthritis patients.
Shahabi A; Shafrin J; Zhao L; Green S; Curtice T; Marshall A; Paul D
J Med Econ; 2019 Apr; 22(4):350-358. PubMed ID: 30653389
[TBL] [Abstract][Full Text] [Related]
12. Economic Burden and Treatment Patterns of Cycling between Conventional Synthetic Disease-modifying Antirheumatic Drugs Among Biologic-treated Patients with Rheumatoid Arthritis.
Betts KA; Griffith J; Ganguli A; Li N; Douglas K; Wu EQ
Clin Ther; 2016 May; 38(5):1205-16. PubMed ID: 27045991
[TBL] [Abstract][Full Text] [Related]
13. Health Care Utilization and Direct Costs Among Patients Diagnosed with Cluster Headache in U.S. Health Care Claims Data.
Choong CK; Ford JH; Nyhuis AW; Robinson RL; Aurora SK
J Manag Care Spec Pharm; 2018 Sep; 24(9):921-928. PubMed ID: 30156448
[TBL] [Abstract][Full Text] [Related]
14. Utilization and costs of medical services and prescription medications for rheumatoid arthritis among recipients covered by a state Medicaid program: a retrospective, cross-sectional, descriptive, database analysis.
Khanna R; Smith MJ
Clin Ther; 2007 Nov; 29(11):2456-67. PubMed ID: 18158087
[TBL] [Abstract][Full Text] [Related]
15. Burden of illness among patients with dementia-related psychosis.
Frazer M; Abler V; Halpern R; Skoog B; Rashid N
J Manag Care Spec Pharm; 2021 Mar; 27(3):367-378. PubMed ID: 33645238
[No Abstract] [Full Text] [Related]
16. Rates, factors, reasons, and economic impact associated with switching in rheumatoid arthritis patients newly initiated on biologic disease modifying anti-rheumatic drugs in an integrated healthcare system.
Rashid N; Lin AT; Aranda G; Lin KJ; Guerrero VN; Nadkarni A; Patel C
J Med Econ; 2016 Jun; 19(6):568-75. PubMed ID: 26766553
[TBL] [Abstract][Full Text] [Related]
17. Demographics, treatment patterns, and healthcare utilization and cost of repository corticotropin injection in patients with systemic lupus erythematosus or rheumatoid arthritis.
Wu B; Deshpande G; Gu T; Popelar B; Philbin M; Wan GJ
J Med Econ; 2017 Nov; 20(11):1170-1177. PubMed ID: 28760047
[TBL] [Abstract][Full Text] [Related]
18. The economic burden of depression among adults with rheumatoid arthritis in the United States.
Li N; Chan E; Peterson S
J Med Econ; 2019 Apr; 22(4):372-378. PubMed ID: 30663460
[TBL] [Abstract][Full Text] [Related]
19. Impact of Switching From an Initial Tumor Necrosis Factor Inhibitor on Health Care Resource Utilization and Costs Among Patients With Rheumatoid Arthritis.
Baser O; Ganguli A; Roy S; Xie L; Cifaldi M
Clin Ther; 2015 Jul; 37(7):1454-65. PubMed ID: 25999184
[TBL] [Abstract][Full Text] [Related]
20. Changes in utilization and costs for patients with rheumatoid arthritis, 1997 to 2006.
Birnbaum HG; Pike C; Banerjee R; Waldman T; Cifaldi M
Pharmacoeconomics; 2012 Apr; 30(4):323-36. PubMed ID: 22379953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
